USP Standards For Biological Drugs Would Restrict Innovation, US FDA Says

 
• By Bowman Cox
  
FDABldg1ExteriorWithCircle_1200x675
FDA officials present their argument against USP monographs for biologics.

More from Manufacturing

More from Compliance